Close Menu
    What's Hot

    Morrisons Retirement Saver Plan Completes Bulk Purchase Annuity Buy-In With Aviva

    28 May 2025

    Yellow Pages Limited Purchases Group Annuity Contracts From BMO Life Assurance Company

    22 May 2025

    Life ILS Conference 2025

    20 May 2025
    Facebook X (Twitter) Instagram
    Instagram LinkedIn X (Twitter)
    Life Risk News
    • Home
    • Features

      New Data Shows the Extent to Which American Seniors Are Missing Out by Lapsing or Surrendering their Life Insurance Policy

      14 May 2025

      Buy-Ins To Buy-Outs Appear Stalled As Deal Complexity, Administration Resources Pose Obstacles

      14 May 2025

      Is Servicing an Overlooked Source of Life Settlement Alpha?

      14 May 2025

      Q&A: Shelly Beard, Managing Director, WTW

      14 May 2025

      Longevity Tech to Emerge as Distinct Sub-Sector of Venture Capital Market?

      14 May 2025
    • Commentary

      UK Life Insurers to Benefit from Robust Bulk Annuity Market in 2025

      14 May 2025

      The Power of Uncorrelated Diversification During Market Volatility

      14 May 2025

      Overseeing BPA Growth Safely

      14 May 2025

      Could Climate Change Cause the Buy-In Market To Collapse?

      10 April 2025

      ICS vs Solvency II: Comparing Risk Corrections for Illiquid Liabilities

      10 April 2025
    • Events
    • Magazine
    • News

      Morrisons Retirement Saver Plan Completes Bulk Purchase Annuity Buy-In With Aviva

      28 May 2025

      Yellow Pages Limited Purchases Group Annuity Contracts From BMO Life Assurance Company

      22 May 2025

      Andrew Limited Pension and Life Assurance Plan Completes Bulk Annuity Transaction With Aviva

      15 May 2025

      Life Insurance Settlement Association Publishes Latest Market Data Collection Survey Results

      13 May 2025

      UK Aggregate Defined Benefit Pension Fund Surplus Down Again in April

      12 May 2025
    Subscribe
    Life Risk News
    Home » Recent Developments in Kidney Disease Treatment to Have Little Short Term Impact on Life Expectancy

    Recent Developments in Kidney Disease Treatment to Have Little Short Term Impact on Life Expectancy

    Features 13 March 2025Greg WintertonBy Greg Winterton
    Twitter LinkedIn Email
    Share
    Twitter LinkedIn Email

    The extent to which someone has chronic kidney disease (CKD) and the actual stage of the CKD is indicated by the estimated glomerular filtration rate (eGFR), a measure of how well the kidneys filter blood.  

    Someone with Stage 1 kidney disease has a GFR of over 90 mL/min and those with Stage 2 kidney disease have a GFR between 60-89 mL/min; there is little cause for concern here, however, and certainly, from a mortality modelling perspective, has little to no impact on life expectancy. Even someone with Stage 3a kidney disease – a GFR of between 45 and 59 mL/min – can lead a normal life, provided that they take medication and make the necessary lifestyle changes. 

    “The progression from Stage 1 to Stage 2 can take many years. The difficulty, however, is actually diagnosing the condition at such an early stage as there will likely be no tell-tale symptoms at that point,” said Fergus Bescoby, Head of Underwriting at CG Analysts.  

    “If someone is diagnosed as having Stage 1 or 2 CKD,  making improvements to their lifestyle along with ensuring adequate control of any secondary conditions (hypertension, diabetes etc) can have a big impact and significantly slow the process of moving through the stages. Our research shows that Stages 1,2 and 3a have no real impact on life expectancy”. 

    It is when someone hits Stage 4 that the alarm bells begin to ring, as a eGFR of 15–29 mL/min means that they have a severe loss of kidney function, with toxins accumulating in the blood.  

    Fatigue, nausea, swelling, loss of appetite, itching, and bone disease are common here, and the individual concerned will be considering their options, which could include dialysis or a kidney transplant – or not. 

    “It is not uncommon for the elderly with Stage 5 CKD (eGFR <15) to refuse dialysis and opt for conservative treatment only. Dialysis can be a burdensome treatment and may reduce quality of life, particularly in patients with other conditions. Dialysis treatment doesn’t always prolong life in patients with other medical conditions and even if it does, much of it may be spent in hospital,” said Bescoby. 

    Dialysis and kidney transplants have been the primary life-sustaining treatments for advanced CKD for over 60 years. Dialysis was first successfully used in the 1940s but became widely available as a standard treatment in the 1970s. The first successful kidney transplant was performed in 1954, with the procedure becoming more common in the 1970s with improvements in immunosuppressive drugs and the establishment of the United Network for Organ Sharing. 

    Since then, however, there has been little change in how advanced kidney disease has been treated, but recent months have delivered two significant developments. 

    The first is in the field of xenotransplantation. In March last year, Richard Slayman, a 62-year-old American man living with kidney failure became the first person to receive a successful transplant of a pig kidney. Slayman sadly died in May 2024, but since then, others have also received kidney transplants, the most recent of whom is Tim Andrews, a 66-year-old who lives in Concord, New Hampshire. 

    In early February, United Therapeutics Corporation announced that the US FDA has approved it to initiate a clinical study of the company’s investigational UKidney, which is derived from a 10 gene-edited source pig. The study will enrol an initial cohort of six end-stage renal disease (ESRD) patients, expanding to up to 50 participants, and is intended to support a Biologics License Application (BLA) with the FDA. United Therapeutics expects the first xenotransplant in this trial to be performed around mid-year 2025. 

    The second is the approval of Ozempic to treat chronic kidney disease among people with type 2 diabetes. 

    These developments could be significant, and for mortality analysts, a rethink may be required. 

    “Treatment for kidney disease, and therefore our understanding of the impact of treatment on mortality has been similar for many years now. It’s imperative that, whenever significant developments like Ozempic come along, underwriters are aware of any potential improvements in life expectancy and revisit their pricing models accordingly”, said Bescoby. 

    The second Thursday in March marks World Kidney Day, which serves to raise awareness of kidney health globally; a wide range of organisations from all corners of the globe put on events designed to educate people about the impact of kidney disease and its associated health problems. 

    And it is exactly those associated problems that underwriters need to factor into their models. Kidney disease was the eighth biggest cause of death of Americans in 2023, but, unlike some of the other impairments on the list, such as cancer or heart disease, CKD is rarely the exclusive cause of death. 

    “CKD is usually caused by other conditions which put strain on the kidneys, for example heart disease, hypertension or diabetes. It is very common in the elderly and if you see an 80-year-old in the life settlement market, the chances of them not having some level of CKD are slim. The cause of death for someone with CKD will generally be one of the secondary conditions, the most common being some form of heart disease”. said Bescoby. 

    There are 92,000 Americans waiting for a kidney transplant, and not nearly enough kidneys. When a kidney does become available, there might be matching issues between donor and potential recipient. When you add to that the understanding of the effectiveness of Ozempic on kidney disease at the population level is still low and the fact that the growth stage of the field of xenotransplantation is embryonic at best adds up to something of a status quo for mortality modellers – for now. 

    “These new developments are hugely encouraging in theory, but much more data is needed to understand more precisely what the impact will be on both population and individual mortality. In life settlements, in particular, we are looking more at the overall picture of the individual than that of the population, and, in the short term, there will likely be little will change to how we view kidney disease,” said Bescoby.  

    “But, if these new treatments show progress in the next few years, then certainly, that could have a noticeable impact on the LE of many individuals.” 

    2025 - March Health Longevity and Mortality Trends Mortality Risk Volume 4 Issue 3 - March 2025
    Share. Twitter LinkedIn Email

    Related Posts

    New Data Shows the Extent to Which American Seniors Are Missing Out by Lapsing or Surrendering their Life Insurance Policy

    14 May 2025

    Buy-Ins To Buy-Outs Appear Stalled As Deal Complexity, Administration Resources Pose Obstacles

    14 May 2025

    Is Servicing an Overlooked Source of Life Settlement Alpha?

    14 May 2025

    Q&A: Shelly Beard, Managing Director, WTW

    14 May 2025

    Comments are closed.

    Most Popular

    New Data Shows the Extent to Which American Seniors Are Missing Out by Lapsing or Surrendering their Life Insurance Policy

    14 May 2025

    Buy-Ins To Buy-Outs Appear Stalled As Deal Complexity, Administration Resources Pose Obstacles

    14 May 2025

    Is Servicing an Overlooked Source of Life Settlement Alpha?

    14 May 2025

    UK Life Insurers to Benefit from Robust Bulk Annuity Market in 2025

    14 May 2025
    Ad

    Your trusted source for capital markets participation in Life Risk

    X (Twitter) Instagram LinkedIn
    Life Risk
    • About Life Risk News
    • Get In Touch
    • Our Team
    • Copyright Notice
    • Terms and Conditions
    • Privacy Policy
    • Sitemap
    Coverage
    • Home
    • Features
    • Events
    • Commentary
    Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT